Handa is focused on developing high-quality prescription medications in two complementary areas: proprietary therapeutics that address significant unmet patient needs, and high-barrier-to-entry generic drugs. We specialize in prescription pharmaceutical products that are difficult to formulate and have the capabilities to manage all aspects of the product development process through the submission of its Abbreviated New Drug Applications (ANDA) and 505(b)(2) New Drug Applications (NDA) to the United States Food and Drug Administration (FDA).

 

Handa developed its proprietary ONCORE^TM technology platform with the goal to create a new class of clinically differentiated Tyrosine Kinase Inhibitors (TKIs) for oncology indications. Our ONCORE^TM technology can enhance molecule specific bioavailability and provide unique clinical benefits that can include but are not limited to (a) no PPI restrictions (can be taken with PPIs/gastric acid reducing agents), or (b) no food effect restrictions (can be taken with or without food). Our ONCORE^TM technology can also reduce pharmacokinetic variability which may reduce the risk of severe adverse events (e.g. QT prolongation, liver toxicity).